Bayer/GSK vardenafil “approvable”
Executive Summary
FDA "approvable" letter for Bayer/GSK's erectile dysfunction drug vardenafil requests "additional short-term clinical pharmacology studies," GSK Chief Operating Officer Robert Ingram tells analysts during July 24 earnings call. The company now projects a launch in the U.S. in 2003. The delay tightens up the race to launch the next erectile dysfunction agent; Lilly/Icos' Cialis is delayed due to manufacturing problems (1"The Pink Sheet" July 22, p. 10). GSK said the brand name Nuviva is no longer under consideration for vardenafil...
You may also be interested in...
Lilly Cialis Head-To-Head Viagra Studies Are Not Enough To Compare – EMEA
Comparative studies submitted in Lilly/Icos' Cialis EU application do not support conclusions about comparative efficacy or safety of the erectile dysfunction therapy versus Pfizer's Viagra, European approval documents maintain
Lilly Cialis Using Alternate Manufacturing Facilities For 2nd Half 2003 Launch
Lilly is preparing alternate manufacturing facilities for Cialis (tadalafil) to expedite the erectile dysfunction product's launch despite Lilly's GMP problems
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.